1. In the Know

2. The GLP-1 RA Class for Type 2 Diabetes

3. Beyond Glycemic Control: Impact of CVOT Data on Clinical Recommendations for T2D

4. Although Both are Incretin-Based Therapies, GLP-1 RAs and DPP-4 Inhibitors Have Different Effects

5. Despite Their Proven Efficacy, Currently Available GLP-1 RAs Are Still Underutilized

6. Novel Mechanism of Action of Oral Semaglutide: Tablet Coformulation with SNAC

7. Administration of Oral Semaglutide

8. Other Novel GLP-1 RAs

9. PIONEER 1-10 Clinical Program

10. PIONEER 2, 3, 4, and 7: Oral Semaglutide vs Active Comparators

11. Summary of Oral Semaglutide Comparative Studies

12. PIONEER 6: CVOT of Oral Semaglutide

13. PIONEER 6: Non-Significant Reduction in MACE and Significant Reduction in Death From CV Causes

14. What to Look Forward To

15. Abbreviations

16. Abbreviations (cont)